NTHI NEONC TECHNOLOGIES HOLDINGS...

Nasdaq neonctech.com


$ 12.00 $ 0.41 (3.59 %)    

Wednesday, 12-Nov-2025 18:47:43 EST
QQQ $ 619.53 $ -3.74 (-0.6 %)
DIA $ 482.77 $ 2.24 (0.47 %)
SPY $ 681.90 $ -1.55 (-0.23 %)
TLT $ 90.02 $ 0.16 (0.18 %)
GLD $ 387.00 $ 5.86 (1.54 %)
$ 11.83
$ 11.50
$ 11.55 x 6
$ 12.00 x 15
-- - --
$ 3.20 - $ 25.00
90,040
na
225.09M
$ -0.31
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-18-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi–Phase 2 clinical-stage biopharmace...

Core News & Articles

NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmace...

Core News & Articles

NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmace...

Core News & Articles

NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmace...

Core News & Articles

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biop...

Core News & Articles

NeOnc Technologies (NASDAQ:NTHI) reported quarterly losses of $(0.30) per share. This is a 11.11 percent decrease over losses o...

Core News & Articles

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for ...

Core News & Articles

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi–Phase 2 clinical-stage biotechnology company focused on breakthrough t...

Core News & Articles

-SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION